Philip Morris International Inc.
Consumer Staples · Tobacco
Structural: ex-US tobacco major pivoting cigarettes → smoke-free (IQOS heat-not-burn + ZYN oral pouches). Swedish Match acquisition (2022, $16B) handed PM the ZYN platform that is now the fastest-growing nicotine category in the US, with shipment volumes lapping +50% YoY off a base that already cleared 500M cans/quarter.
IQOS converts adult smokers in 90+ markets; PM regained US IQOS rights from $MO in 2024 ahead of a 2026 US relaunch.
- Smoke-free now ~40% of net revenues, growing double-digit while combustibles decline single-digit - mix shift is margin-accretive.
- ZYN US capacity expansions (Owensboro KY + Colorado) targeting 900M+ cans/quarter unlocks supply-constrained demand.
- IQOS US relaunch (2026) under PM ownership opens the largest premium nicotine market.
- Pricing power on combustibles funds smoke-free reinvestment; FCF supports 5%+ dividend yield.
- Regulatory tailwind: FDA MRTP authorizations for ZYN + IQOS Iluma raise category moat.
- FDA/EU flavor bans or PMTA denials on ZYN/IQOS would compress the smoke-free thesis.
- Currency drag: ~70% of revenue ex-US, USD strength compresses reported growth.
- $MO + $BTI competing nicotine-pouch entries (on!, Velo) eroding ZYN share at the margin.
- Combustible volume declines accelerating in legacy markets faster than smoke-free can offset.
- Net leverage elevated post-Swedish Match; refi risk if rates stay higher for longer.
No key levels recorded for this ticker.